KOD · Kodiak Sciences Inc.
$37.32
-0.18 (-0.48%)
At close · Sep 3
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.33B
Shares
62.85M
KOD metrics
51 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$37.50
Market cap
$2.33B
Price action
19 metricsPrice change (1W)
-6.1%
Price change (30D)
-7.0%
Price change (3M)
+11.6%
Price change (6M)
+40.2%
Price change (YTD)
+32.5%
Price change (1Y)
+310.0%
Trailing year
Price change (5Y)
-61.7%
52-week high
$46.44
52-week low
$8.55
Change from 52-week high
-20.2%
Change from 52-week low
+333.5%
Annualized volatility
127.9%
Beta
1.2
RSI (14D)
39.7
Price vs SMA 50
-7.9%
Price vs SMA 200
+12.7%
Avg volume (3M)
703,006
Relative volume
0.6
Average dollar volume
$26.86M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
62.85M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
38.1
reciprocal yield 2.6%
FCF yield
-6.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-11-13
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$246.42M
Net income (TTM)
−$241.99M
Trailing 12 months
Diluted EPS (TTM)
$-4.19
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-396.1%
Return on assets
-94.2%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$159.90M
Quick ratio
2.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$125.90M
Total assets
$256.81M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$158.50M
Capital expenditures (TTM)
$1.40M
R&D (TTM)
$200.60M
SG&A (TTM)
—
Stock compensation (TTM)
$51.09M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
203
13F filer change QoQ
+12
Institutional ownership
98.3%
Short interest
3 metricsShort interest
16.4%
Latest settlement · 17.5 days to cover
Days to cover
17.5d
Short-squeeze score
67 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged